Head-to-head evidence
Ciclesonide (XRP1526) vs fluticasone furoate/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Ciclesonide (XRP1526)
Developed by Sanofi
NCT00174720 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial, 708 patients with asthma were randomized to one of several ciclesonide dosing regimens or placebo. Ciclesonide produced significantly greater improvements in lung function (FEV1) than placebo, both averaged over weeks 12-16 and at week 16 alone.
fluticasone furoate/vilanterol
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciclesonide (XRP1526)'s landscape · fluticasone furoate/vilanterol's landscape